Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 - 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth of Roche's haematology portfolio and pipeline, and commitment to developing innovative treatment solutions for patients in need.

Roche Holding AG veröffentlichte diesen Inhalt am 05 November 2020 und ist allein verantwortlich für die darin enthaltenen Informationen.
Unverändert und nicht überarbeitet weiter verbreitet am 05 November 2020 14:08:06 UTC.

Originaldokumenthttps://www.roche.com/de/media/releases/med-cor-2020-11-05.htm

Public permalinkhttp://www.publicnow.com/view/4BD77C5E6C8F2DEA6FB3AB4B735ECD4DDC8526E9